CTRI/2025/10/096284Not yet recruitingUnknown
A Clinical study to evaluate the Sun protection factor of Honasa ME Vitamin C Daily Glow Sunscreen (AP5I076)
Honasa Consumer Pvt. Ltd1 site in 1 country10 target enrollmentStarted: November 5, 2025
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Change in Individual MED (iMED) score
Study Overview
Brief Summary
This is the Invivo SPF test done as per UV-B protection ISO 24444 to determine the Sun Protection Factor
Test Product:
1. ME Vitamin C Daily Glow Sunscreen (AP5I076)
Done on 10 human volunteers. Duration: 3 Days
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Individual should have ITA angle in the range of 18 t0 40, 41 to 55, and greater than 56
- •Individuals free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the investigator.
- •Individuals who have completed a preliminary medical history evaluation.
- •Individuals who have read, understood and signed an informed consent document relating to the specific study to which they are subscribing.
- •Individuals with no known abnormal response to sunlight.
Exclusion Criteria
- •1.Individuals taking medication which in the opinion of the investigator would mask or interfere with the results.
- •2.Individuals with chronic skin allergies.
- •3.Individuals with suntan or sunburn.
- •4.Individuals with abnormal reaction to the sun.
- •5.Pregnant or lactating females.
- •6.Subjects accustomed to using sun beds.
- •7.Subjects who have participated in an SPF study within the last two months.
Outcomes
Primary Outcomes
Change in Individual MED (iMED) score
Time Frame: Day1, Day2, Day3
Secondary Outcomes
- Not Applicable(Not Applicable)
Investigators
Dr Robin Chugh
CCFT Laboratories
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Unknown
Efficacy and Safety of Baypure Vitamin C & Ferulic Acid SerumCTRI/2025/10/096426Baypure Lifestyle Pvt Ltd35
Not yet recruiting
Phase 1
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaAplastic AnemiaNCT07287228Institute of Hematology & Blood Diseases Hospital, China37
Completed
Phase 1
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
Recruiting
Not Applicable
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation TreatmentNCT07387978Peter MacCallum Cancer Centre, Australia30
Recruiting
Phase 1
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)NCT07331272Nanjing Legend Biotech Co.38